In Brief: Guidant/Hewlett-Packard
This article was originally published in The Gray Sheet
Guidant/Hewlett-Packard: Sign agreement to develop and market a new high-frequency intravascular ultrasound diagnostic catheter. Under the terms of the deal, HP will develop the IVUS imaging core. Guidant will act as the original equipment manufacturer of the catheter sheath and will market the finished product. The agreement expands on two previous deals between the firms -- an August 1996 agreement for use of HP's IVUS technology in Guidant's SureCut guided directional coronary atherectomy catheter ("The Gray Sheet" Sept. 2, 1996, I&W-4), and a November 1996 agreement for distribution of HP's coronary and peripheral IVUS catheters and consoles by Guidant...
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.